Guillain-Barré Syndrome (GBS) - Pipeline Insight, 2025

The “Guillain-Barré Syndrome (GBS) - Pipeline Insight, 2025” report provides comprehensive insights about 2+ companies and 3+ pipeline drugs in Guillain-Barré Syndrome (GBS) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Guillain-Barré Syndrome (GBS): Understanding

Guillain-Barré Syndrome (GBS): Overview

Guillain-Barré Syndrome (GBS) is a rare neurological disorder in which the immune system mistakenly attacks part of the peripheral nervous system, the network of nerves located outside of the brain and spinal cord. GBS can range from a very mild case with brief weakness to nearly devastating paralysis, leaving you unable to breathe independently. Fortunately, most people eventually recover from even the most severe cases of GBS. After recovery, some people will continue to have some degree of weakness. GBS can increase in intensity over a period of hours, days, or weeks until certain muscles cannot be used at all and, when severe, the person is almost totally paralyzed. In these cases, the disorder is life-threatening, potentially interfering with breathing and, at times, with blood pressure or heart rate..

Two characteristic symptoms of GBS are Weakness and Sensory Changes. Weakness is usually symmetrical and worsens within hours or days, with most individuals reaching their peak weakness within two weeks. Sensory changes, such as tingling, pain, or the sensation of insects crawling under the skin, are common, particularly in the feet or hands. Other symptoms can include difficulty with eye muscles, swallowing, speaking, and chewing, along with coordination problems, severe pain (especially at night), and autonomic issues like abnormal heart rate, blood pressure, and digestion.

Antecedent infections, particularly with Campylobacter jejuni, are found in up to 70% of Guillain-Barré Syndrome (GBS) cases, with molecular mimicry playing a key role in the disease’s development. The lipooligosaccharide of Campylobacter jejuni shares similarities with gangliosides on peripheral nerve membranes, triggering immune responses that damage the nerves. Specific antibodies, such as anti-GD1a, anti-GM1, and anti-GQ1B, target different components of peripheral nerves, influencing the clinical presentation of GBS. For instance, Miller-Fisher syndrome is linked to anti-GQ1B antibodies, while axonal motor neuropathy is associated with anti-GM1 antibodies. However, not all GBS patients test positive for these antibodies, suggesting the need for further research to better understand their role and the pathophysiology of GBS.

The diagnosis of Guillain-Barré Syndrome (GBS) relies on clinical history, examination, and supportive tests like cerebrospinal fluid (CSF) analysis and electrodiagnostic studies, as there are no specific biomarkers. The two main diagnostic criteria are the NINDS criteria (1978), which is more clinically focused and includes typical and atypical GBS features, and the Brighton Collaboration criteria (2011), which helps classify GBS or Miller-Fisher Syndrome (MFS) based on diagnostic certainty. Differential diagnoses must be considered, as GBS shares symptoms with several other disorders, making early diagnosis challenging. There is no cure for Guillain-Barré Syndrome (GBS), but treatments like plasma exchange (plasmapheresis) and intravenous immunoglobulin (IVIg) can help reduce immune-related nerve damage and shorten recovery time if started early. Hospital care focuses on preventing complications, such as respiratory support, pain management, and physical therapy. Rehabilitation helps regain strength and independence. While most people recover fully, some may experience residual weakness, fatigue, and long-term complications, requiring ongoing care and psychological support.

"Guillain-Barré Syndrome (GBS)- Pipeline Insight, 2025" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Guillain-Barré Syndrome (GBS) pipeline landscape is provided which includes the disease overview and Guillain-Barré Syndrome (GBS) treatment guidelines. The assessment part of the report embraces, in depth Guillain-Barré Syndrome (GBS) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Guillain-Barré Syndrome (GBS) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Guillain-Barré Syndrome (GBS) R&D. The therapies under development are focused on novel approaches to treat/improve Guillain-Barré Syndrome (GBS).

Guillain-Barré Syndrome (GBS) Emerging Drugs Chapters

This segment of the Guillain-Barré Syndrome (GBS) report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Guillain-Barré Syndrome (GBS) Emerging Drugs

• ANX005: Annexon, Inc.

ANX005, is a first-of-its kind selective, targeted and rapid-acting agent designed to reduce inflammation and nerve damage by stopping C1q activity in the peripheral and central nervous systems. In GBS, ANX005 is designed to seek out C1q and prevent its binding to targets on peripheral nerves. ANX005 is administered intravenously and has been observed to act almost immediately in blocking C1q function. The aim of an effective treatment in GBS is to rapidly stop the autoimmune damage on nerve cells, allowing patients to regain muscle strength sooner and to regain independence and return to pre-illness activities. ANX005 has received both Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration as well as orphan drug designation from the European Medicines Agency for the treatment of GBS. Currently the drug is in Phase III stage of Clinical trial evaluation for the treatment of Guillain-Barré Syndrome (GBS).

• Imlifidase: Hansa Biopharma

Imlifidase is a unique antibody-cleaving enzyme originating from Streptococcus pyogenes that specifically targets IgG and inhibits IgG-mediated immune response. It has a rapid onset of action, cleaving IgG-antibodies and inhibiting their activity within hours after administration. imlifidase can effectively and very rapidly remove immunoglobulin G through enzymatic cleavage - halting the progression of nerve damage associated with GBS and stopping disease progression. By rapidly reducing harmful IgG antibodies, imlifidase could potentially halt the progression of GBS, leading to quicker recovery and improved functional outcomes for patients. The U.S. Food and Drug Administration has also granted Orphan Drug Designation to imlifidase for the treatment of GBS Currently, the drug is in Phase II stage of its development for the treatment of Guillain-Barré Syndrome (GBS).

Guillain-Barré Syndrome (GBS): Therapeutic Assessment

This segment of the report provides insights about the different Guillain-Barré Syndrome (GBS) drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Guillain-Barré Syndrome (GBS)

• There are approx. 2+ key companies which are developing the therapies for Guillain-Barré Syndrome (GBS). The companies which have their Guillain-Barré Syndrome (GBS) drug candidates in the most advanced stage, i.e. Phase III include, Annexon, Inc.

Phases

The report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Guillain-Barré Syndrome (GBS) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Guillain-Barré Syndrome (GBS): Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Guillain-Barré Syndrome (GBS) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Guillain-Barré Syndrome (GBS) drugs.

Guillain-Barré Syndrome (GBS) Report Insights

• Guillain-Barré Syndrome (GBS) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Guillain-Barré Syndrome (GBS) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Guillain-Barré Syndrome (GBS) drugs?
• How many Guillain-Barré Syndrome (GBS) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Guillain-Barré Syndrome (GBS)?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Guillain-Barré Syndrome (GBS) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Guillain-Barré Syndrome (GBS) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Annexon, Inc.
• Hansa Biopharma

Key Products

• ANX005
• Imlifidase

This product will be delivered within 2 business days.